Nav: Home

Vanderbilt joins national consortium to develop new cancer therapies

August 19, 2009

NASHVILLE, Tenn. - Vanderbilt University has been selected as one of 10 centers in the nation to participate in the Chemical Biology Consortium (CBC), a major new initiative to facilitate the discovery and development of new agents to treat cancer.

As one of four Chemical Diversity Centers, Vanderbilt's role in the consortium will be to synthesize and optimize new compounds as potential cancer therapeutics.

"This is a real tribute to our growth in cancer chemistry and the leverage between the Vanderbilt Institute of Chemical Biology (VICB) and the Vanderbilt-Ingram Cancer Center (VICC)," said Lawrence Marnett, Ph.D., the Mary Geddes Stahlman Professor of Cancer Research and director of the VICB.

Alex Waterson, Ph.D., research assistant professor of Pharmacology and director of the VICB's Chemical Synthesis Core, will lead efforts developing small molecule drug candidates. Gary Sulikowski, Ph.D., Stevenson Professor of Chemistry and a co-director of the core, will direct projects involving natural products.

Designed to accelerate the discovery and development of effective, first-in-class targeted therapies, the CBC will choose high-risk targets that are of low interest to the pharmaceutical industry. The CBC is a National Cancer Institute initiative administered by contractor SAIC-Frederick, Inc.

"It's exciting in the sense that, right off the bat, (the NCI) said that the goal of this program is to develop drugs for cancer treatment," said Sulikowski. "They're looking for unique targets, unique approaches, and they think that academia may offer that."

"Oftentimes pharmaceutical companies will not go after targets that are not expected to be huge blockbusters," said Waterson, who came to Vanderbilt in 2008 from GlaxoSmithKline where he had worked for seven years on oncology drug development projects. "So an effort like this can fill in a niche that industry is not taking on at the moment."

One particular area of interest is in screening and developing natural products as potential drug candidates.

This "is something that pharmaceutical industry has de-emphasized just because of the way things have evolved," said Sulikowski. "And that's one of our advantages, in that we have expertise in natural products as well as medicinal chemistry."

Cancer drug development poses many challenges - but also unique opportunities.

"There is a difficulty in that cancer is not a single disease; it's a family of loosely related diseases," said Waterson. "There's an opportunity for a whole myriad of different treatments that are pretty much only tailored to a small subset of people, where your treatment addresses their specific need."

A unique aspect of the CBC is the NCI's efforts to establish intellectual property rights for investigators and institutions that develop assays or drug candidates.

"The hope is that by recognizing establishment of intellectual property as one of the goals, they will attract people with the best ideas, things that really might be able to become a drug," said Waterson.

Vanderbilt's involvement with the CBC, along with the recent arrival of Stephen Fesik, Ph.D., who previously led cancer drug discovery efforts at Abbott Laboratories, will make Vanderbilt "one of the best academic institutions doing cancer drug discovery in the country," Marnett said.

Other Vanderbilt investigators involved in this effort include:
  • Brian Bachmann, Ph.D., assistant professor of Chemistry and Biochemistry
  • Jeffrey Johnston, Ph.D., professor of Chemistry
  • Jens Meiler, Ph.D., assistant professor of Chemistry, Pharmacology and Biomedical Informatics
  • Craig Lindsley, Ph.D., associate professor of Pharmacology and Chemistry, and director of Medicinal Chemistry
Other sites participating in the CBC are:
  • The Burnham Institute for Medical Research, in La Jolla, Calif.;
  • Southern Research Institute in Birmingham, Ala.;
  • University of North Carolina at Chapel Hill;
  • Georgetown University in Washington, D.C.;
  • University of Minnesota;
  • University of Pittsburgh;
  • University of Pittsburgh, Drug Discovery Institute;
  • University of California, San Francisco;
  • SRI International in Menlo Park, Calif.; and
  • Emory University in Atlanta
-end-
This project has been funded in whole or in part with Federal Funds from the National Cancer Institute, National Institutes of Health, under Contract No. NO1-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Vanderbilt University Medical Center

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...